Many older people purchase the hormone melatonin and consume it orally, each evening, to promote the onset of sleep at bedtime and, particularly, the resumption of sleep after premature nocturnal awakenings. This need for exogenous melatonin to supplement that secreted from the aging pineal arises from the gland's progressive, agerelated calcification, which decreases the number of active pineal cells, causing parallel reductions in melatonin's synthesis and secretion.
about its generally minor side effects, as would be obligatory for hypnotic drugs or for other hormones, such estrogens or thyroxine. This is because, from a regulatory standpoint, orally-administered melatonin is classified not as a drug or hormone but as a 'dietary supplement'-even though no food has ben compellingly shown to contain more than trace amounts of authentic melatonin, nor has consumption of any food been shown by gas-chromatography-mass-spectroscopy to elevate plasma melatonin levels. And, by virtue of the Dietary Supplement Health and Education Act of 1994, dietary supplements are regulated as though they are foods, (which do not require prior FDA approval) rather than as drugs, so long as their marketers make only 'structure or function claims' relating to effects on normal people, and do not promote the supplements for treating disease states. Supplements are not subject to the safety and efficacy testing requirements imposed on drugs, and the FDA may take action against their sale only after they have been shown to be unsafe (which, fortunately, has not been the case for melatonin).
Recently the first official regulatory body-the European Food Safety Authority (EFSA)-evaluated the available evidence that melatonin can reduce the time it takes for normal sleepers and patients with insomnia to fall asleep. 7 It concluded that the evidence from all three of the statistically valid meta-analyses that have been published [8] [9] [10] affirms '… a cause and effect relationship … between the consumption of melatonin and 
Melatonin, Melatonin Receptors, and Sleep
Melatonin, a derivative of the circulating amino acid tryptophan, was discovered by Aaron Lerner in 1958, based on its ability to lighten the skin color of amphibians, in vitro. We then showed, in 1963, that melatonin functions as a hormone in mammals, 1 which the pineal gland produces and sectretes when the animals are exposed to darkness. 1, 11 In 1975 our laboratory further showed that blood melatonin levels in humans are also about tenfold higher during the hours of darkness than in daytime. 11 This finding was interpreted as suggesting that the hormone might have something to do with sleep in humans and other diurnally active animals. Lerner had, in fact, described feeling 'relaxed' after selfadministering a very large dose of melatonin (200 mg i.v.); however, the hormone's possible relationship to sleep was not systematically explored until the 1990s, when it was found that giving single melatonin doses to normal young subjects during the daytime caused dose-related, parallel increases in sleepiness, sleep, and plasma melatonin levels. 5 Peak effects were observed after surprisingly low doses ( 0.3-1.0 mg), which elevated plasma melatonin to the same levels (100-200 pcg/ml) as those normally occurring in young people at nighttime. 
Melatonin and the Insomnia Associated with Aging
In 1982 it had been demonstrated that nocturnal plasma melatonin levels in most humans decline with aging 2 -a probable consequence of the stillunexplained tendency of the human pineal to calcify. Since this decline was known to coincide with a common age-related sleep problem, i.e. frequent nocturnal awakenings followed by difficulty in falling back asleep, 4 we investigated whether giving older people melatonin at bedtime, as a 'hormone replacement therapy' (i.e. providing them with a dose sufficient to restore nocturnal plasma levels to those of young adults) would also suppress nocturnal awakenings and shorten the time needed to resume sleeping. Again, the melatonin doses now recommended by the EFSA (0.3-1.0 mg, which raise plasma melatonin levels to the range that normally occurs nocturnally in young people) was found to help the patients to remain asleep or readily fall back asleep 4 throughout most of the night.
These observations, which have been widely confirmed, led to oral melatonin's widespread use for promoting and sustaining sleep, particularly among older people. However, for the most part, patients
have not been able to use the lowest fully effective doses, because only substantially higher doses have been commercially available to them. Such doses, which raise plasma melatonin to levels many times higher than those in younger people, produce side effects not observed at the lower, more physiologic sleep-promoting doses, for example, hypothermia, 1, 4 hyperprolactinemia, 6 and morning grogginess. 5 As described above, the markedly elevated melatonin levels also can desensitize the MT1 and MT2 receptors in brain on which melatonin acts 12-14 e.g. to promote sleep, quite possibly causing some users to become refractory to the beneficial effects of the melatonin they take 4 or their own pineal glands secrete.
Using Available Melatonin Preparations to Treat the Insomnia of Aging
We may wonder why it is that physiologic doses of melatonin-which elevate its plasma levels within their normal range in younger people-generally available, which purportedly provide a high enough total dose (e.g. 1.0 or 2.0 mg 16, 17 ) to elevate plasma melatonin for most of the night, but probably not so much as would produce desensitizing peak levels.
Or one of the new melatonin preparations, available on the internet, that provides within a single capsule both a melatonin solution containing an immediately available 0.3 mg, and a resin that slowly releases an additional 0.3-0.6 mg later in the night.
Few data are available on the plasma melatonin curves produced by such preparations, nor about how well these plasma curves correlate with sleep efficiency and sleep time. It should be noted that the bioavailability and pharmacokinetics of oral melatonin differ slightly between younger (29.5 years) and older adults (60 years). 18 As discussed above, young subjects exhibit significantly higher peak endogenous serum melatonin levels than older subjects, with greater inter-individual variability; however, older subjects exhibit higher and somewhat more variable serum levels after a 0.3 mg oral dose than younger ones. Hence, some older subjects might, for long-term daily use, actually require doses even lower than 0.3 mg. 18 n
